Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from BTIG Research

Sionna Therapeutics (NASDAQ:SION)‘s stock had its “buy” rating reiterated by stock analysts at BTIG Research in a report issued on Wednesday,Benzinga reports. They currently have a $58.00 price objective on the stock. BTIG Research’s price target indicates a potential upside of 49.29% from the company’s previous close.

Several other research firms have also recently commented on SION. Raymond James Financial restated a “strong-buy” rating and issued a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Royal Bank Of Canada restated an “underperform” rating and set a $24.00 price objective on shares of Sionna Therapeutics in a research note on Monday, December 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Finally, Lifesci Capital initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $45.43.

Sionna Therapeutics Stock Down 5.7%

Shares of NASDAQ:SION opened at $38.85 on Wednesday. The company’s 50-day moving average price is $40.67 and its 200 day moving average price is $30.56. The company has a market cap of $1.73 billion and a PE ratio of -7.98. Sionna Therapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insider Buying and Selling

In related news, Director Orbimed Advisors Llc sold 94,583 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $44.54, for a total value of $4,212,726.82. Following the sale, the director directly owned 3,610,376 shares in the company, valued at $160,806,147.04. The trade was a 2.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael Cloonan sold 99,800 shares of the firm’s stock in a transaction that occurred on Tuesday, October 21st. The stock was sold at an average price of $36.26, for a total transaction of $3,618,748.00. Following the sale, the chief executive officer owned 547,343 shares of the company’s stock, valued at $19,846,657.18. The trade was a 15.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 1,071,548 shares of company stock worth $42,687,226. 3.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in shares of Sionna Therapeutics during the fourth quarter valued at $440,000. Millennium Management LLC raised its holdings in Sionna Therapeutics by 1,425.5% during the 3rd quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock worth $6,296,000 after buying an additional 200,051 shares during the period. Jain Global LLC purchased a new stake in Sionna Therapeutics during the third quarter valued at about $250,000. Bank of America Corp DE lifted its stake in Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after buying an additional 529 shares in the last quarter. Finally, Longaeva Partners L.P. acquired a new position in shares of Sionna Therapeutics in the third quarter worth about $1,807,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.